DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 276 participants.

Also called NCT04124484

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 276 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04124484
Other papers using this trial's data
  • Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial Current medical research and opinion, 2020-07 DOI, PubMed 32338063

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04124484. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-17 (actual); primary completion 2019-02-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DBPR108 Tablets in Type 2 Diabetes Mellitus Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)
Intervention (Drug)
DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)
Intervention (Drug)
DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)
Intervention (Drug)
Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)
Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04124484
Content hash
4a92aa0716f7e965e112b47453d7b956574ddaff6a01428898b3f64c3740fb34